XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
Series A Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Jun. 30, 2022 $ 5 $ 116 $ 145,574,080 $ (122,492,176) $ 23,082,025
Balance (in shares) at Jun. 30, 2022 484,582 11,592,173      
Series A preferred stock issued for employee stock compensation     13,864   13,864
Series A preferred stock issued for employee stock compensation (in shares) 10,591        
Common stock issued for consulting and legal services rendered     27,000   27,000
Common stock issued for consulting and legal services rendered (in shares)   12,710      
Warrants issued to Scientific Advisory Board     480   480
Common stock issued for Directors fees     11,250   11,250
Common stock issued for Directors fees (in shares)   5,154      
Net Income (Loss) $ 0 $ 0 0 (1,570,642) (1,570,642)
Balance at Sep. 30, 2022 $ 5 $ 116 145,626,674 (124,062,818) 21,563,977
Balance (in shares) at Sep. 30, 2022 495,173 11,610,037      
Balance at Jun. 30, 2022 $ 5 $ 116 145,574,080 (122,492,176) 23,082,025
Balance (in shares) at Jun. 30, 2022 484,582 11,592,173      
Forgiveness of interest on related party debt         0
Net Income (Loss)         (3,315,776)
Balance at Dec. 31, 2022 $ 5 $ 116 145,678,202 (125,807,952) 19,870,371
Balance (in shares) at Dec. 31, 2022 495,560 11,634,576      
Balance at Sep. 30, 2022 $ 5 $ 116 145,626,674 (124,062,818) 21,563,977
Balance (in shares) at Sep. 30, 2022 495,173 11,610,037      
Series A preferred stock issued for employee stock compensation     13,055   13,055
Series A preferred stock issued for employee stock compensation (in shares) 387        
Common stock issued for consulting and legal services rendered     27,000   27,000
Common stock issued for consulting and legal services rendered (in shares)   17,366      
Warrants issued to Scientific Advisory Board     223   223
Common stock issued for Directors fees     11,250   11,250
Common stock issued for Directors fees (in shares)   7,173      
Net Income (Loss)       (1,745,134) (1,745,134)
Balance at Dec. 31, 2022 $ 5 $ 116 145,678,202 (125,807,952) 19,870,371
Balance (in shares) at Dec. 31, 2022 495,560 11,634,576      
Balance at Jun. 30, 2023 $ 5 $ 116 145,946,258 (131,080,749) 14,865,630
Balance (in shares) at Jun. 30, 2023 547,674 11,698,497      
Series A preferred stock issued for employee stock compensation     9,617   9,617
Series A preferred stock issued for employee stock compensation (in shares) 10,591        
Common stock issued for consulting and legal services rendered   $ 1 50,599   50,600
Common stock issued for consulting and legal services rendered (in shares)   39,103      
Warrants issued to Scientific Advisory Board     159   159
Common stock issued for Directors fees     11,250   11,250
Common stock issued for Directors fees (in shares)   7,947      
Net Income (Loss)       (1,968,746) (1,968,746)
Balance at Sep. 30, 2023 $ 5 $ 117 146,017,882 (133,049,494) 12,968,510
Balance (in shares) at Sep. 30, 2023 558,265 11,745,547      
Balance at Jun. 30, 2023 $ 5 $ 116 145,946,258 (131,080,749) 14,865,630
Balance (in shares) at Jun. 30, 2023 547,674 11,698,497      
Common stock issued for consulting and legal services rendered (in shares)   62,482      
Common stock issued for Directors fees (in shares)   17,664      
Forgiveness of interest on related party debt         49,808
Net Income (Loss)         (4,083,683)
Balance at Dec. 31, 2023 $ 9 $ 117 147,615,441 (135,164,431) 12,451,136
Balance (in shares) at Dec. 31, 2023 890,511 11,778,643      
Balance at Sep. 30, 2023 $ 5 $ 117 146,017,882 (133,049,494) 12,968,510
Balance (in shares) at Sep. 30, 2023 558,265 11,745,547      
Series A preferred stock issued for employee stock compensation     9,358   9,358
Series A preferred stock issued for employee stock compensation (in shares) 387        
Series A preferred stock issued upon conversion of related party promissory note $ 4   1,499,996   1,500,000
Series A preferred stock issued upon conversion of related party promissory note (in shares) 331,859        
Common stock issued for consulting and legal services rendered     27,000   27,000
Common stock issued for consulting and legal services rendered (in shares)   23,379      
Warrants issued to Scientific Advisory Board     147   147
Common stock issued for Directors fees     11,250   11,250
Common stock issued for Directors fees (in shares)   9,717      
Forgiveness of interest on related party debt     49,808   49,808
Net Income (Loss)       (2,114,937) (2,114,937)
Balance at Dec. 31, 2023 $ 9 $ 117 $ 147,615,441 $ (135,164,431) $ 12,451,136
Balance (in shares) at Dec. 31, 2023 890,511 11,778,643